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Introduction {#sec1}
============

Dendritic cells (DCs) are mononuclear phagocytes crucial for the initiation and regulation of immune responses ([@bib40]). They are classically divided into plasmacytoid DCs (pDCs) and two distinct subsets of conventional DCs (cDCs), termed cDC1 and cDC2 ([@bib15]). The cDC1 subset constitutes a homogeneous cell population identified by surface expression of the chemokine receptor XCR1 and the C-type lectin DNGR-1 (also known as CLEC9A) in both mice and humans ([@bib8], [@bib32]) and is defined by its developmental dependence on the transcription factors BATF3 and IRF8 ([@bib2], [@bib17], [@bib26]) and the growth factors fms-like tyrosine kinase 3 ligand (FLT3L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) ([@bib12], [@bib14], [@bib24], [@bib25]). cDC1s play a prominent role in cross-presentation of dead cell-associated antigens and in Th1 and cytotoxic T lymphocyte priming ([@bib25]). cDC2s are CD11b^+^ CD172a^+^, and their differentiation depends on IRF4, IRF2, TRAF6, RelB, and RBP-J transcription factors ([@bib26]). However, mouse CD11b^+^ cDC2s are considerably heterogeneous and include a subtype whose differentiation depends on KLF4 and induces Th2-dominated immunity ([@bib42]) as well as gut CD103^+^CD11b^+^ DCs that prominently induce Th17 responses against pathobionts ([@bib30], [@bib37]). Human cDC2s are often identified as HLA-DR^+^ CD11c^+^ CD11b^+^ CD1a^+^ CD1c^+^ leukocytes ([@bib6], [@bib10]) with variable expression of CD14 ([@bib20]). As for mice, human cDC2 are heterogeneous ([@bib43]) and, in some cases, can be contaminated with monocyte progeny that is referred to as "monocyte-derived DCs" and has a similar surface phenotype ([@bib23]). Additional DC subtypes have very recently been described in human blood, suggesting that DC heterogeneity may be even greater than previously appreciated ([@bib43]).

DCs are derived from hematopoietic progenitors that are continuously produced in adult bone marrow by hematopoietic stem cells (HSCs) ([@bib25]). Early studies indicated that mouse and human common myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs) both have the potential to generate DCs, suggesting that DCs can be generated by either myelopoiesis or lymphopoiesis ([@bib7], [@bib18], [@bib22], [@bib41]). However, a fate-mapping experiment using IL7Ra-Cre excluded a significant contribution of lymphoid progenitors to DC generation and placed DCs squarely within the myelopoietic branch ([@bib36]). Consistent with that notion, a current view of DC development is that CMPs give rise to macrophage/DC progenitors (MDPs), first identified in mice and then in humans ([@bib11], [@bib20]), which further differentiate into a common DC progenitor (CDP) that is no longer able to generate monocytes ([@bib20], [@bib27], [@bib29]). In turn, CDPs give rise to circulating pre-DCs that leave the bone marrow and travel via the blood to seed lymphoid and non-lymphoid organs, giving rise to differentiated DCs ([@bib5], [@bib12], [@bib21], [@bib38]). This model of DC development supports a classical view of hematopoiesis where DC specification occurs through stepwise loss of multi-lineage potential by myeloid progenitors ([@bib1], [@bib19], [@bib33]).

That model was challenged by a barcoding study that analyzed the progeny of mouse early lymphoid multipotent primed progenitors (LMPPs) ([@bib28]). It found that a large proportion of LMPPs is already imprinted with the potential to give rise to cDCs independently of monocytes or granulocytes. In addition, a re-analysis of putative mouse MDPs found that only a very small fraction of cells was truly bi-potential at the clonal level ([@bib35]). Altogether, these findings would seem to indicate that the differentiated mouse cDC pool might reflect a mixed contribution of MDPs as well as cDC-imprinted LMPPs, as argued for the pDC lineage ([@bib39]). Similarly, in humans, early lympho-myeloid progenitors might contribute to DC generation because the multipotent lymphoid progenitor (MLP; Lin^−^CD34^+^CD38^−^CD45RA^+^CD10^+^) can generate monocytes and HLA-DR^+^ CD1a^+^ CD11c^+^ CD11b^+^ cells in addition to all lymphoid cells ([@bib10]). However, it remains unclear whether the HLA-DR^+^ CD1a^+^ CD11c^+^ CD11b^+^ cells generated by human lympho-myeloid progenitors correspond to bona fide conventional cDC2 or, instead, reflect a monocyte-derived DC. A more stringent test of the cDC-generating potential of MLPs would be to assess whether the precursor population can give rise to cDC1, but this has not been reported. Finally, it is unclear whether different DCpoietic pathways, if they exist, would give rise to identical cells. Here we tested the potential of CMPs versus MLPs to generate human cDC1 and cDC2 cells. We report that human MLPs can efficiently generate both cDC1s and cDC2s and that MLP- and CMP-derived cDC1 cells are transcriptionally indistinguishable. These results support a model in which specification of the cDC lineage can occurs early in hematopoiesis in humans and underscore the diversity of hematopoietic decisions giving rise to identical human DCs.

Results {#sec2}
=======

MLPs, CMPs, and GMPs Can Generate cDCs In Vitro and In Vivo {#sec2.1}
-----------------------------------------------------------

We have previously shown that unfractionated CD34^+^ umbilical cord blood hematopoietic cells can be differentiated in vitro into CD1a^+^HLA-DR^+^CD141^+^DNGR-1^+^ cDC1s ([@bib31], [@bib32]) under the aegis of FLT3-L, stem cell factor (SCF), GM-CSF, and interleukin-4 (IL-4) (FSG4). This culture condition also allows the differentiation of CD1c^+^ cDC2 cells and of CD14^+^ monocytes ([@bib3]; see below). To analyze the actual origin of DCs developing in FSG4 cultures, we isolated different hematopoietic progenitors from human cord blood by flow cytometry ([Figure 1](#fig1){ref-type="fig"}A) following established protocols ([@bib1], [@bib7], [@bib10]) to sort MLPs, CMPs, and granulocyte/macrophage progenitors (GMPs), which originate from CMPs but are now known to also overlap in phenotype with DC precursors ([@bib20]). MLPs, CMPs, and GMPs all express FLT3 ([@bib10], [@bib20]), allowing them to respond to FLT3L, a key pre-requisite for DC differentiation ([@bib9]). Sorted MLP, CMP, and GMP populations were then cultured with FSG4, and their DC- and monocyte/macrophage (mono/mac)-generating potential was analyzed.Figure 1MLPs, CMPs, and GMPs Can Generate cDCs In Vitro(A) Gating strategy for human hematopoietic progenitors isolated from umbilical cord blood. Boxes depict gates, and numbers correspond to the percentage of cells in each gate.(B) 500 of the indicated progenitor cells isolated according to the gating strategy in (A) were cultured for 12 days in vitro with FLT3-L, IL-4, SCF, and GM-CSF. CD141^+^DNGR-1^+^ cDC1, CD14^+^CD1a^−^ mono/mac, and CD14^−^CD1a^+^CD1c^+^ cDC2 progeny were analyzed by flow cytometry. Contour plots depict the gating strategy used to identify cDC1s, cDC2s, and mono/macs. Graphs show the percentage (left) and numbers (right) of each phagocyte subtype produced and are the average of three independent cultures. Error bars depict SD. ^∗^ p \< 0.05 (one-way ANOVA). Data are from one experiment representative of at least four independent experiments.

We found that MLPs, CMPs, and GMPs were all able to expand in the FSG4 culture system ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and give rise to CD141^+^DNGR-1^+^ cDC1, CD1a^+^CD1c^+^CD14^−^ cDC2, and CD1a^−^CD14^+^ mono/macs ([Figure 1](#fig1){ref-type="fig"}B). MLPs were efficient cDC1 progenitors both in terms of percentage and number of CD141^+^DNGR-1^+^ cells generated and were less efficient at generating cDC2s by the same criteria ([Figure 1](#fig1){ref-type="fig"}B). GMPs were similar in efficiency to MLPs at generating CD141^+^DNGR-1^+^ cDC1s, but, intriguingly, CMPs only gave rise to modest numbers of the same DCs. However, CMPs were as efficient as MLPs at generating cDC2s and mono/macs in the FSG4 culture system ([Figure 1](#fig1){ref-type="fig"}B). We tested whether the different progenitors produced CD141^+^DNGR-1^+^ cDC1s with different kinetics. We found that CMPs, GMPs, and MLPs followed the same kinetics of differentiation into CD141^+^DNGR-1^+^ cDC1s, with a peak around day 13 in FSG4 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). We then tested whether the low cDC1-generating potential of CMPs could be rescued by adding other cytokines to the FSG4 cocktail. All cytokines tested (IL-6, M-CSF, and G-CSF) extinguished rather than improved cDC1 generation by CMPs ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Finally, we tested the lineage potential of the progenitors in a more permissive cytokine environment comprising FLT3-L, SCF, and GM-CSF (FSG) ([Figure S1](#mmc1){ref-type="supplementary-material"}E). This cytokine cocktail enables the differentiation of all DC subsets (cDC1s, cDC2s, and pDCs) as well as natural killer (NK) cells, monocytes, and granulocytes ([@bib20]). Similar to FSG4 cultures, MLP was the most efficient producer of CD141^+^DNGR-1^+^ cDC1s. MLP was also the only progenitor giving rise to CD56^+^ NK cells and to CD303^+^ pDCs, which were phenotypically distinct from DNGR-1^+^ cDC1s ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). In contrast, CMPs and GMPs were more efficient at generating CD14^+^ monocytes and CD66b^+^ granulocytes ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Altogether, these results show that MLPs are the most efficient cDC1 progenitors in various culture settings.

To confirm these results in vivo, we transferred MLPs, CMPs, and GMPs into non-obese diabetic (NOD)/severe combined immunodeficiency (SCID)/IL-2Rγ-null/Tg(CMV-IL3, CSF2, KIT ligand \[KITLG\]) (NSG-SGM3) mice ([@bib4]). Two weeks later, DC content was analyzed in the bone marrow of recipients. In mice receiving MLPs, CD141^+^DNGR-1^+^ cDC1s represented around 40% of all human CD45^+^ cells, whereas, in CMP recipients, this only reached 10% ([Figure 2](#fig2){ref-type="fig"}). In contrast, all progenitors gave rise to a similar low frequency of cDC2s, whereas GMPs were slightly more efficient than CMPs or MLPs at generating CD14^+^ mono/macs. As expected, only MLPs could generate CD19^+^ B cells, confirming their lymphoid potential ([Figure S2](#mmc1){ref-type="supplementary-material"}). Interestingly, MLPs were also the only progenitors able to give rise to pDCs ([Figure S2](#mmc1){ref-type="supplementary-material"}). Together, these results show that, at bulk population level, CMPs, GMPs, and MLPs can all give rise to cDC1s, cDC2s, and mono/macs. CMPs appear to be biased toward cDC2 and mono/mac generation, whereas MLPs produce relatively more cDC1s and pDCs both in vitro and in vivo. Thus, commitment to the human cDC lineage can occur in early hematopoietic progenitors with myeloid or lympho-myeloid potential in various experimental settings. Importantly, MLPs present the best potential for cDC1 and pDC production compared with CMPs and GMPs.Figure 2MLPs, CMPs, and GMPs Can Generate cDCs In VivoIrradiated NSG-SGM3 mice were injected intravenously with different human progenitors. Two weeks later, human cDC1, cDC2, and monocyte presence in the bone marrow was quantitated by flow cytometry. Contour plots and graphs show the generation of CD141^+^DNGR-1^+^ cDC1, CD14^−^CD11c^+^CD1c^+^ cDC2, and CD14^+^CD1c^−^ cells by the different progenitors. Each dot represents an individual mouse, bars indicate the mean, and error bars indicate SD. ^∗^p \< 0.05 (one-way ANOVA). Data are a pool of two independent experiments.

Single-Cell Potential of DC Progenitors {#sec2.2}
---------------------------------------

To assess the potential of the different progenitors to generate mononuclear phagocytes at the single-cell level, we set up an in vitro clonal assay in which single MLPs, GMPs, or CMPs were isolated and cultured with MS5 stromal cells and FSG4 for 12 days (see [Figure S3](#mmc1){ref-type="supplementary-material"}A for cloning efficiency). The ability to generate cDC2s and mono/macs did not differ strikingly among different progenitors and was found in 40%--60% of the starting populations ([Figure 3](#fig3){ref-type="fig"}A). This confirms that DC- and mono/mac-generating potential is not restricted to a small fraction of contaminating cells in any of the populations. The cloning efficiency of MLPs was low, which could be due to an effect of combining FSG4 with MS5 without re-optimizing the cytokine cocktail (unpublished observations). Nevertheless, we found that more than 50% of the MLPs that generated detectable clones in MS5 + FSG4 cultures could give rise to cDC1s ([Figure 3](#fig3){ref-type="fig"}A). Moreover, a higher frequency of MLPs could generate cDC2s than give rise to mono/macs ([Figure 3](#fig3){ref-type="fig"}A), and approximately 37% of single MLPs could differentiate into cDCs (cDC1s and cDC2s) without generating other myeloid cells ([Figure 3](#fig3){ref-type="fig"}B). This was not the case for the CMPs, which never generated cDC-only progeny ([Figure 3](#fig3){ref-type="fig"}B). These findings suggest that some hematopoietic progenitors are pre-imprinted with the potential to give rise to cDCs independently of mono/mac. To explore this notion, we first focused on the cDC1 subset, which is more homogeneous than cDC2 ([@bib43]) and, therefore, a reliable indicator of cDC commitment. The percentage of cDC1s generated by individual MLPs or GMPs varied between 1% and 99% ([Figure 3](#fig3){ref-type="fig"}C, top; [Figure S3](#mmc1){ref-type="supplementary-material"}B), which suggests the presence inside of MLP and GMP populations of a spectrum of cells that have global myeloid potential versus cDC-only potential. In contrast, the percentage of cDC1s generated by individual CMPs never reached more than 10%, confirming the absence of clones with a cDC-only potential ([Figure 3](#fig3){ref-type="fig"}C, top; [Figure S3](#mmc1){ref-type="supplementary-material"}B). We then analyzed cDC2 generation efficiency under the same conditions. Similar to cDC1 generation, the percentage of cDC2s generated by individual MLPs and GMPs varied between 1% and 99% ([Figure 3](#fig3){ref-type="fig"}C, bottom). Interestingly, CMPs were more efficient on a per-cell basis at generating cDC2s than cDC1s because some CMP clones could generate more than 50% of cDC2s. This could suggest that CMPs and MLPs generate different subsets of cDC2s ([@bib43]), although this was not assessed. Consistent with their cDC-restricted potential, about 40% of MLPs and GMPs, but no CMPs, expressed, at the single-cell level, mRNA for *IRF8* ([Figure 3](#fig3){ref-type="fig"}D), the key cDC1-specifying factor. In addition, among MLPs and GMPs expressing *IRF8*, 50% of MLPs but only 10% of GMPs had higher levels of *IRF8* mRNA per cell ([Figure 3](#fig3){ref-type="fig"}D; [Figure S3](#mmc1){ref-type="supplementary-material"}C). Finally, only 5% of MLP clones expressed mRNA for myeloperoxidase (MPO), a marker of myeloid commitment that was found in over 50% of GMPs ([Figure 3](#fig3){ref-type="fig"}D). Altogether, these data indicate that early and multipotent lymphoid-primed progenitors such as MLPs, but not myeloid progenitors such as CMPs, contain cells with high potential for cDC generation that can even give rise to a single cDC subset (cDC1).Figure 3Single-Cell Potential of DC Progenitors(A) Single progenitor cells were deposited on a layer of MS5 cells and cultured for 12 days with FLT3-L, IL-4, SCF, and GM-CSF. cDC1, cDC2, and mono/mac presence in each well was analyzed by flow cytometry. Bars represent the percentage of wells that contained each of the indicated populations irrespective of the presence or absence of any others. The actual number of wells is indicated on top of each bar. Data are a pool of four independent experiments.(B) Bar graph showing the percentage of single progenitors producing only cDC1 cells (pink), only cDC2 cells (green), or only cDC1 and cDC2 cells (black). White includes wells that gave rise to other cell types with or without cDCs. Contour plots show an example for single GMP or MLP culture wells containing only cDC1 and cDC2.(C) cDC1 and cDC2 generation in single-cell cultures. The graphs illustrate the percentage of cDC1 (top) or % of cDC2 (bottom) detected in each cDC1- or cDC2-positive well seeded with single CMPs, MLPs, or GMPs. The data are a pool of four independent experiments. The lines represent the mean.(D) Bar graphs representing the percentage of IRF-8^+^ (left) or MPO^+^ (right) single progenitor cells among total GAPDH^+^ cells, as determined by single-cell qRT-PCR. The actual number of IRF-8^+^ or MPO^+^ cells compared with the total number of GAPDH^+^ cells is indicated on top of each bar. The center graph shows the relative expression (RE) of IRF8 compared with GAPDH for each IRF8-positive cell. ^∗^p \< 0.001 represents statistically significant differences in expression between GMPs and MLPs (unpaired t test). Data are from one experiment representative of two independent experiments.

MLP- and CMP-Derived cDC1s Are Transcriptionally Identical {#sec2.3}
----------------------------------------------------------

Although cDC1s are thought to be homogeneous, the finding that CD1a^+^HLA-DR^+^CD141^+^DNGR-1^+^ cells could be generated from MLPs (efficiently) or CMPs (less efficiently) prompted the question of whether they are the same cells. We therefore carried out a transcriptomic analysis of MLP- or CMP-derived cDC1s and compared both profiles with a published dataset of DC subsets and monocyte-derived DC (MoDCs) generated in vitro from total CD34^+^ HSCs or purified from peripheral blood ([@bib3]). We found that both MLP- and CMP-derived cDC1s expressed the classical cDC1 gene signature, which includes, among others, *IRF8*, *TLR3*, *CLEC9A*, and *XCR1* transcripts ([Figure 4](#fig4){ref-type="fig"}A; [Figure S4](#mmc1){ref-type="supplementary-material"}). We could also confirm that MLP- and CMP-derived cDC1 did not express any of the signature genes of MoDCs or pDCs ([Figure 4](#fig4){ref-type="fig"}A; [Figure S4](#mmc1){ref-type="supplementary-material"}). We then compared MLP- or CMP-derived cDC1s with each other by principal component analysis. This revealed that MLP- and CMP-derived cDC1s clustered tightly together ([Figure 4](#fig4){ref-type="fig"}B) and did not display any statistically significant differences in gene expression (data not shown). As expected, MLP- and CMP-derived cDC1s were closest to cDC1 produced in vitro from CD34^+^ HSC/progenitors or purified from human blood ([Figure 4](#fig4){ref-type="fig"}B). This was confirmed by unsupervised hierarchical clustering using the 2% of genes with the most variable expression ([Figure 4](#fig4){ref-type="fig"}C). We conclude that MLP- and CMP-derived CD141^+^DNGR-1^+^ cells are indistinguishable and represent phenotypically bona fide cDC1s.Figure 4MLP- and CMP-Derived cDC1 Transcriptomic Analysis(A) Heatmap of gene expression values comparing MLP- and CMP-derived cDC1 populations with a published dataset (GSE57671) of cord blood CD34^+^ cell-derived cDC1s and MoDCs as well as MoDCs derived from purified blood monocytes and primary cDC1, cDC2, and pDCs purified from peripheral blood ([@bib3]). Individual replicates are shown.(B) Principal component analysis of all genes expressed in MLP- and CMP-derived cDC1 cells and in DC populations described in [@bib3]. Each dot of the same color corresponds to a replicate sample.(C) Hierarchical clustering of triplicate samples of MLP- and CMP-derived cDC1s and published dataset of cord blood CD34^+^ cell-derived cDC1s and MoDCs as well as MoDCs derived from blood monocytes and primary blood cDC1s, cDC2s, and pDCs ([@bib3]). The 2% of genes with the most variable expression were used for the analysis.

Discussion {#sec3}
==========

DCpoiesis is often thought to constitute a branch of myelopoiesis. Our study shows that human cDC progenitors are enriched within the pool of early hematopoietic progenitors, the MLPs, that gives rise to lymphoid cells. This result mirrors a recent study in mice that used barcoding to follow in vivo the cellular output of single LMPPs and found that 50% of the cells were imprinted toward the cDC lineage ([@bib28]). In contrast, another study has recently identified a human MDP in the CD34^+^ fraction of human umbilical cord blood and bone marrow, consistent with the classical view that DCs derive from a myeloid branch-producing progenitors with increased commitment toward the DC lineage ([@bib20]). However, [@bib20] show that only 13% of single MDPs are able to generate both cDCs and monocytes ([@bib20]). Similarly, in mice, the bi-potentiality of single MDPs is found in a small fraction of cells ([@bib35]). Therefore, bi-potent monocyte/cDC progenitors may co-exist with CDPs that derive directly from MLPs and do not have an MDP ancestor.

In humans, the phenotype of the GMP overlaps partially with that of DC precursors ([@bib20], [@bib38]). The GMP population is therefore likely to be heterogeneous and contain a substantial fraction of DC precursors, unlike the CMP population ([@bib20]), explaining why GMPs appear to be more efficient than their CMP progenitors at generating DCs. In contrast, DC progenitors do not overlap in phenotype with MLPs, and our findings of efficient DC generation by MLPs cannot be ascribed to a small sub-fraction of contaminating cells because cDC-generating potential was present in more than 50% of cloneable MLPs. This is consistent with the fact that around half of all MLPs express IRF8, a transcription factor that has been shown to auto-activate and trigger cDC1 subset differentiation ([@bib13]) and the loss of which leads to human DC deficiency ([@bib16]). Therefore, as in mice, human DCs appear to have two types of progenitors. One "late" progenitor shared with monocytes ([@bib11], [@bib20]) and one found very early in the hematopoietic tree at the MLP level ([@bib28]). Which of these progenitors contributes most to the steady-state pool of cDCs is unknown.

These results, suggesting a dual ontogeny of cDCs, led us to ask whether cDC1 cells deriving from distinct developmental pathways are equivalent. The latter would indicate an overriding role of "nurture" in cDC differentiation, whereas the former would suggest that cellular "nature" leaves an indelible imprint in progeny at the level of gene expression and, perhaps, function. Interestingly, we found an exclusive role for nurture in that MLP-derived and CMP-derived cDC1s possess identical transcriptomes. Because gene expression underlies cell function, we presume that both sources of cDC1s lead to cells with identical properties, although we did not perform exhaustive functional analyses. Interestingly, mouse pDCs can also originate from either myelo- or lymphopoietic branches and are seemingly identical, other than displaying or not displaying a history of recombination activating gene (RAG) expression ([@bib34], [@bib39]). Whether distinct pathways of DC production prevail in different settings remains to be explored, as does the possibility that, under some circumstances, cDCs derived from MLPs and those derived from MDPs may acquire different functional properties.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

NOD/SCID/IL-2Rγ-null mice transgenic for human SCF, IL3, and GM-CSF (NSG-SGM3) were bred at the Francis Crick Institute under specific pathogen-free conditions. Age- and sex-matched mice were used for all experiments. All experiments were performed in accordance with national and institutional guidelines for animal care and were approved by the Francis Crick Institute Animal Ethics Committee and by the United Kingdom Home Office.

Human Cells {#sec4.2}
-----------

Umbilical cord blood from healthy neonates was obtained from the Anthony Nolan Cell Therapy Centre under an agreement that includes ethical approval for laboratory research use. Mononuclear cells were obtained by density centrifugation using Ficoll-Paque (GE Healthcare) and ammonium chloride red cell lysis.

Flow Cytometry Analysis {#sec4.3}
-----------------------

Cells were stained in ice-cold PBS containing fetal calf serum (FCS, 2%) and EDTA (2 mM) using appropriate antibody-fluorophore conjugates. Prior to staining for DNGR-1, cells were pre-incubated on ice with mouse serum (Jackson ImmunoResearch Laboratories) and purified immunoglobulin G2a (IgG2a, BioLegend) to block Fc receptors. See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for antibodies used. Multiparameter acquisition was performed on a Fortessa analyzer (BD Biosciences), and data were analyzed with FlowJo software (Tree Star). Prior to acquisition, cells were resuspended in PBS/FCS and 2%/EDTA (2 mM) solution with 1 μg/ml of DAPI to exclude dead cells.

Cell Sorting {#sec4.4}
------------

Cells were sorted on a BD FACS Aria (BD Biosciences). For sorting of progenitors, mononuclear cells were isolated from umbilical cord blood, and lineage-negative cells were enriched using magnetic beads. Briefly, cells were incubated with Fc-block (BD Biosciences) for 10 min, stained with fluorescein isothiocyanate (FITC)-conjugated antibodies against lineage markers (Lin1-FITC) and washed before incubation with anti-FITC beads and enrichment on LD columns (both from Miltenyi Biotec). The flow-through fraction was stained with antibodies and sorted by FACS to achieve 99% purity. Dead cells were excluded using DAPI.

In Vitro Cultures {#sec4.5}
-----------------

500--2,000 purified progenitors were cultured for 12 days in Iscove's Modified Dulbecco's Medium (IMDM) culture medium (Gibco) supplemented with β-mercaptoethanol and 10% heat-inactivated FCS at 37°C, together with the following cytokines (R&D Systems): human fms-like tyrosine kinase 3 ligand (hFLT3L) (100 ng/mL), human stem cell factor (hSCF) (20 ng/mL), human interleukin-4 (hIL-4) (20 ng/mL), and human granulocyte-macrophage colony-stimulating factor (hGM-CSF) (20 ng/mL). Half of the medium containing the cytokine cocktail was replaced every 3 days. In single-cell culture experiments, MS5 mouse fibroblast feeder cells were seeded in 96 well-culture plates (flat bottom) the day before to achieve 60%--70% confluence (3,000 MS5 cells/well). Single progenitors were then sorted directly onto the MS5 cell layer, and medium with cytokines was added subsequently.

In Vivo Transfer {#sec4.6}
----------------

Mice ages 8--12 weeks were sub-lethally irradiated (2 Gy) up to 24 hr before intravenous (i.v.) injection of 5,000--10,000 sorted CMPs, MLPs, or GMPs. The bone marrow of reconstituted mice was analyzed 2 weeks later.

Single-Cell qPCR {#sec4.7}
----------------

Single MLPs, CMPs, or GMPs were sorted directly into dry 96-well PCR plates and frozen at −80°C. See the Supplemental Experimental Procedures for cDNA production. qPCR for IRF8, MPO, and GAPDH was performed with TaqMan Universal PCR MasterMix (Applied Biosystems) and predesigned primers and probe mixes (TaqMan gene expression assays, Applied Biosystems). Measurements were performed using a sequence detection system (ABI Prism 7700, Applied Biosystems). The levels of mRNA for the specific gene being measured were divided by those for GAPDH measured in parallel (normalized expression).

Microarrays {#sec4.8}
-----------

CD141^+^DNGR-1^+^ cDC1 cells were sorted according to the gating strategy depicted in [Figure 1](#fig1){ref-type="fig"}B (upper panels) to achieve 99% purity. For each population, total RNA was extracted using an RNeasy Micro- or Minikit (QIAGEN). RNA was hybridized to the Affymetrix Human Gene 2.0 ST array according to the manufacturer's instructions. Each analysis was performed in triplicate using independently sorted cells from independent cultures. See the Supplemental Experimental Procedures for the microarray analysis.

Statistical Analysis {#sec4.9}
--------------------

Statistical analyses were performed using GraphPad Prism as indicated in the figure legends. For the microarray analysis, differentially expressed genes were assessed using an empirical Bayes t test. The p values were adjusted using the Benjamini-Hochberg method. Microarrays data from a previous study used for comparative analysis are available under accession number GEO: [GSE57671](ncbi-geo:GSE57671){#intref0010}.
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